Invest Shanghai

Cookies need to be enabled to log on

HOME > INVESTMENT DYNAMICS > DYNAMICS OF FOREIGN INVESTMENT

Type:

INVESTMENT DYNAMICS NPC and CPPCC Annual Sessions 2026 DO BUSINESS NEWS AND TRENDS POLICY UPDATES DYNAMICS OF FOREIGN INVESTMENT OVERSEAS INSTITUTION UPDATES HONG KONG, MACAO AND TAIWAN STATISTICS OTHER INFORMATION WHAT'S NEW USEFUL INFORMATION

2026
Mar.30

[DYNAMICS OF FOREIGN INVESTMENT] Rolls-Royce blends Chinese ancient craft with identity for Bespoke luxury
For Rolls-Royce Motor Cars, luxury takes time, even centuries, a fact exemplified by the brand's latest Bespoke exploration, which incorporates China's thousand-year-old handmade paper into its cars…
2026
Mar.30

[DYNAMICS OF FOREIGN INVESTMENT] Gap to open 50 new China stores in 2026
Gap Inc plans to open about 50 new stores in the Chinese market this year, as its local operator, Baozun Inc, accelerates expansion to sustain double-digit growth in the world's second-largest appar…
2026
Mar.27

[DYNAMICS OF FOREIGN INVESTMENT] Shanghai's Foreign Firms Move Beyond Sales to Build Innovation Hubs
A growing number of international companies in Shanghai are fast-tracking their transformation, moving beyond their traditional roles as management, sales and service centers to become innovation as…
2026
Mar.27

[DYNAMICS OF FOREIGN INVESTMENT] UK's GSK Allies With Shanghai Pharma to Bring Hepatitis B Jab Back to China
GlaxoSmithKline has joined hands with Shanghai Pharmaceutical to reintroduce the UK pharmaceutical giant's hepatitis B vaccine to the Chinese market after nearly four years. GSK has allied with SPH …
2026
Mar.27

[DYNAMICS OF FOREIGN INVESTMENT] DHL Teams Up With China’s JA Solar, Haier to Boost Green Supply Chains, Support Global Expansion
Global logistics giant DHL Group is linking arms with Chinese solar technology manufacturer JA Solar and the logistics arm of home appliance firm Haier Group to accelerate the green and intelligent …
2026
Mar.27

[DYNAMICS OF FOREIGN INVESTMENT] China's Faster Drug Reviews Make It a Key Launch Market, Boehringer Exec Says
China’s drug review and approval process has become faster than ever before, making it an increasingly important launch destination for innovative medicines, according to a senior executive at Germ…
2026
Mar.26

[DYNAMICS OF FOREIGN INVESTMENT] Organon sees opportunities in China's push for high-quality population development
Organon, a global healthcare company, said China's efforts to improve population development and advance a more health-centered medical system are creating fresh opportunities for global healthcare …
2026
Mar.25

[DYNAMICS OF FOREIGN INVESTMENT] Foreign firms eye fresh opportunities in China's push to boost consumption
As China steps up efforts to improve domestic consumption, multinational companies are increasingly positioning themselves to tap what they see as one of the world's most significant sources of futu…
2026
Mar.24

[DYNAMICS OF FOREIGN INVESTMENT] Novartis announces further China investment
Swiss pharmaceutical company Novartis is to expand its research and development, manufacturing capacity and operations footprint in China, with planned investment of more than 3.3 billion yuan ($460…
2026
Mar.23

[DYNAMICS OF FOREIGN INVESTMENT] AstraZeneca to build cell therapy manufacturing facility in Lin-gang
United Kingdom-headquartered pharmaceutical company AstraZeneca announced plans on March 19 to establish a commercial cell therapy manufacturing facility in Shanghai's Lin-gang Special Area, making …

LOAD MORE